Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CytoMed Therapeutics Limited ( (GDTC) ) has shared an update.
On November 6, 2025, CytoMed Therapeutics announced securing a non-dilutive investment from ICH Capital for its subsidiary LongevityBank, which focuses on autologous therapies. The investment will help LongevityBank expand its personalized cellular banking services. Additionally, CytoMed is exploring a new strategy in China, leveraging recent regulatory changes to introduce its allogeneic gamma delta T cell platform. This strategic move is expected to enhance CytoMed’s market positioning in Southeast Asia and China, potentially benefiting stakeholders by expanding treatment options and improving accessibility to innovative cancer therapies.
The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by declining revenues and cash flow deficits. Technical analysis provides some positive signals, but these are overshadowed by poor valuation metrics, including a negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that focuses on developing novel, affordable donor-derived cell-based immunotherapies for treating a wide range of cancers, including both blood and solid tumors. The company leverages its proprietary technologies, such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create allogeneic immunotherapies inspired by the success of CAR-T therapies.
Average Trading Volume: 72,882
Technical Sentiment Signal: Sell
Current Market Cap: $23.35M
For a thorough assessment of GDTC stock, go to TipRanks’ Stock Analysis page.